Aktienanalyse zu 111 Inc (YI)YI111 Inc

111 Inc is an investment holding company primarily engaged in the operation of integrated online and offline healthcare platform. The Company mainly operates its business through two segments. The Business to Customer (B2C) segment is engaged in the sale of pharmaceutical and other health and wellness products through 1 Medicine Marketplace, mobile apps, other online channels and offline pharmacies to consumers and certain enterprise customers. The Business to Business (B2B) segment is engaged in the sale of pharmaceutical products to pharmacies on 1 Pharmacy. The Company also provides customers with online consultation and electronic prescription services through the Internet hospital 1 Clinic. The Company’s products include drugs, nutritional supplements, medical supplies and devices and other products. The Company mainly conducts its business in the domestic market. It operates in the Healthcare sector (DRUG STORES AND PROPRIETARY STORES industry).

Currently, 111 Inc (YI) is not a strong buy due to its significant financial challenges. The stock is trading at $2.90, with a 52-week high of $11.17, indicating a potential for recovery, but the RSI is at 36.67, suggesting it is nearing oversold territory. However, the company reported a 33.1% year-over-year revenue decline in Q1 2026 and a net income of -$37.04 million in Q1 2026, which raises concerns about its profitability and future growth prospects. The main risk is the company's high debt-to-equity ratio of 1199.60%, indicating significant financial leverage and potential liquidity issues.

1 analysts cover YI: 1 rate it Buy, 0 Hold and 0 Sell.